stockrow
Friday 6 November 2026
Export DNTH’s income statement to Excel — free account
Dianthus Therapeutics, Inc.
DNTH Healthcare Biotechnology
Dianthus Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.0 million, down 67.3% from fiscal 2024.
- Revenue
- +205.6%
- EPS
- +16.1%
- Free cash flow
- −65.9%
Quarter to September 2026, against a year earlier
86.43
3.42
+4.12%
Follow DNTH
Alert me
Dianthus Therapeutics, Inc. (DNTH) Revenue growth
Dianthus Therapeutics, Inc.'s revenue growth over the twelve months to 30 September 2026 was −11.7%, up 55.6 percentage points from fiscal 2025 (−67.4%). That is below the Biotechnology industry median of 6.76% and below the Healthcare sector median of 7.98%.
Revenue growth, annual
Embed this chart
Annual newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| FY2025 | −67.4% | (187.98) |
| FY2024 | 120.6% | 176.59 |
| FY2023 | −56.0% | — |
Quarterly newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| Sep 2026 | 205.6% | (88.74) |
| Jun 2026 | 294.3% | 354.49 |
| Mar 2026 | −60.2% | 18.39 |
| Dec 2025 | −78.6% | 3.19 |
| 9 more quarters | Free account |
Revenue growth against peers
| Company | Revenue growth |
|---|---|
| COGT Cogent Biosciences, Inc. compare | 110.2% |
| LEGN Legend Biotech Corporation Sponsored ADR compare | 59.6% |
| TVTX Travere Therapeutics, Inc. compare | 49.4% |
| DNTH Dianthus Therapeutics, Inc. | −11.7% |
| CRSP CRISPR Therapeutics AG compare | −34.3% |
| EWTX Edgewise Therapeutics, Inc. compare | — |
| DFTX Definium Therapeutics, Inc. compare | — |
| ERAS Erasca, Inc. compare | — |
| MANE Veradermics Incorporated compare | — |
| Biotechnology industry median | 6.76% |
| Healthcare sector median | 7.98% |
| Market median | 7.71% |
What Revenue growth is
Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.
(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|
More on DNTH
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Altman Z-score
- Beneish M-score
- The full statement